Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities. (PubMed, Cancers (Basel)) - Aug 28, 2026 - "Although FDA-approved JAK1/JAK2 inhibitors ruxolitinib, fedratinib pacritinib and momelotinib effectively reduce splenomegaly and symptom burden and have demonstrated survival benefits in clinical trials, their ability to eliminate malignant clones or induce durable disease modification remains limited, and disease progression continues to occur in most patients. Finally, this review assesses the complex immunological dysfunction and chronic inflammatory dysregulation that characterize Ph-negative MPNs, as well as emerging therapeutic strategies, emphasizing the importance of fully understanding these intricate microenvironmental mechanisms for the identification and development of novel precision treatment targets."
Journal • Review • Cardiovascular • Essential Thrombocythemia • Fibrosis • Hematological Disorders • Immunology • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis • Thrombosis • CALR
|
|
Ali Keyhani; Ali Rafat; Faride Kaikavoosnejad; Hamed Mirzaei; Khadijeh Dizaji Asl; Milad Verdi; Mohammad Sepehr Yazdani; Reza Nejati; Seyyede Sepide Ashraf Moosavi; Zeinab Mazloumi
|